| Code | CSB-RA004843MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Mogamulizumab-KPKC, targeting the CC chemokine receptor 4 (CCR4). CCR4 is a G protein-coupled receptor preferentially expressed on T helper 2 (Th2) cells, regulatory T cells (Tregs), and certain subsets of effector T cells. This receptor plays a crucial role in immune cell trafficking and homing to inflammatory sites through interactions with its ligands CCL17 and CCL22. CCR4 is notably overexpressed on malignant T cells in adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, making it a valuable therapeutic target in hematological malignancies.
Mogamulizumab-KPKC is a defucosylated humanized IgG1 kappa monoclonal antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) against CCR4-positive cells. This biosimilar provides researchers with a valuable tool for investigating CCR4-mediated signaling pathways, studying tumor immunology, evaluating immune cell migration mechanisms, and exploring novel therapeutic strategies for T-cell malignancies and immune-mediated disorders.
There are currently no reviews for this product.